Zogenix News Banner

NEWS

2008

Zogenix, Inc. Files Registration Statement for Proposed Initial Public Offering

March 24th, 2008

Zogenix Announces sumatriptan DosePro™ NDA Accepted for Filing by FDA

March 19th, 2008

Zogenix Licenses European Development and Commercial Rights for sumatriptan DosePro™ to Desitin Pharmaceuticals, GmbH

March 17th, 2008

Zogenix Raises $18 Million in Preferred Stock Financing

January 9th, 2008

2007

Zogenix Licenses Exclusive U.S. Commercial Rights for Late Stage, Controlled-Release, Opioid Product from Elan

November 27th, 2007

Stephen J. Peroutka, M.D., Ph.D. Joins Zogenix As Chief Medical Officer

November 1st, 2007

Zogenix Appoints David Nassif Executive Vice President and Chief Financial Officer

June 7th, 2007

Zogenix Closes $10 Million Deal with GE Healthcare Financial Services

March 19th, 2007

News Archives

2006

Zogenix Appoints J.D. Haldeman Vice President, Commercial Strategy & Corporate Communications

Zogenix, Inc. Names Founding Management Team

Zogenix, Inc. Raises $60 Million In Series A Venture Financing; Names Board of Directors

Aradigm Announces Asset Sale of Intraject^® Needle-Free Technology; Private Company Created to Launch Novel Migraine Treatment